Praxis Precision's Price Target Raised to $700 by Truist
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 20 2026
0mins
Should l Buy PRAX?
Source: stocktwits
- Price Target Increase: Truist raised its price target for Praxis Precision from $500 to $700 while maintaining a ‘Buy’ rating, reflecting strong confidence in the company's future growth, particularly in light of the FDA's positive review backdrop.
- FDA Application Update: Praxis recently submitted market approval applications for ulixacaltamide and relutrigine to the FDA; although Wedbush holds reservations about ulixacaltamide, management anticipates acceptance notifications by mid-April, which could further drive stock price increases.
- Strong Financial Position: Praxis reported a net loss per share of $3.5 for Q4 2025, slightly above the analyst estimate of $3.1, but with $926.1 million in cash and equivalents, the company expects to fund operations through 2028, indicating solid financial health.
- Optimistic Market Sentiment: On Stocktwits, retail sentiment around PRAX stock remains in the ‘bullish’ territory with high message volume, reflecting investor optimism about the company's future, and the average 12-month price target is $599.94, suggesting an upside potential of about 81%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRAX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRAX
Wall Street analysts forecast PRAX stock price to rise
15 Analyst Rating
14 Buy
0 Hold
1 Sell
Strong Buy
Current: 309.010
Low
95.00
Averages
456.71
High
843.00
Current: 309.010
Low
95.00
Averages
456.71
High
843.00
About PRAX
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The Company is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms, using its understanding of shared biological targets and circuits in the brain. Its platform includes Cerebrum, a small-molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, an antisense oligonucleotide platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The Company’s product candidates include ulixacaltamide, vormatrigine, relutrigine, PRAX-080, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Xenon Pharmaceuticals Reports Positive Phase 3 X-TOLE2 Study Results
- Positive Study Results: Xenon Pharmaceuticals announced positive topline results from the Phase 3 X-TOLE2 study of azetukalner in focal onset seizures, with a placebo-adjusted median percentage change of -42.7% in the 25 mg group, significantly outperforming the previous Phase 2b study results.
- Primary Endpoint Achieved: The study met its primary endpoint, with 54.8% of participants in the 25 mg group achieving at least a 50% reduction in monthly seizure frequency compared to 20.8% in the placebo group, demonstrating the efficacy of azetukalner.
- Future Application Plans: Xenon plans to submit a New Drug Application (NDA) to the FDA in Q3 2026, and if approved, azetukalner will be the only KV7 potassium channel opener available for epilepsy treatment, potentially transforming the treatment landscape for patients with uncontrolled seizures.
- Positive Market Reaction: Xenon shares rose 16.17% to $48.72 in premarket trading on Monday, reflecting strong investor response to the study results, while analysts maintain a Buy rating with an average price target of $56.78.
See More
Praxis Grants Restricted Stock Units to New Employees
- Employee Incentive Program: On March 2, 2026, Praxis Precision Medicines granted 2,931 restricted stock units to fourteen new non-executive employees, aimed at attracting top talent in compliance with Nasdaq Listing Rule 5635(c)(4).
- Stock Unit Vesting Schedule: The restricted stock units will vest in four equal annual installments, contingent upon the employees' continued employment, thereby aligning employee interests with the company's long-term goals and enhancing retention rates.
- Strategic Talent Acquisition: This grant is part of the 2024 Inducement Plan, specifically designed to attract individuals who were not previously employed by the company, highlighting Praxis's commitment to talent acquisition and its competitive edge in the biopharmaceutical industry.
- Company Overview: Praxis is a leading CNS precision neuroscience biopharmaceutical company focused on translating insights from genetic epilepsies into therapies for CNS disorders, boasting multiple late-stage product candidates that demonstrate strong R&D capabilities and market potential.
See More
Baker Bros. Increases Praxis Stake to 1.94% with $81.38M Purchase
- Stake Increase: Baker Bros. Advisors increased its stake in Praxis Precision Medicines by 437,000 shares during Q4 2025, valued at $81.38 million, indicating strong confidence in the company's future prospects.
- Market Valuation Growth: The post-trade valuation of Praxis increased by $295.48 million due to trading activity and price movements, reflecting positive market sentiment towards its clinical-stage therapies.
- R&D Investment: In 2025, Praxis reported R&D expenses of $267.1 million, with a net loss of $303.3 million, yet the company remains committed to advancing its treatments for central nervous system disorders.
- Cash Flow Position: As of the end of 2025, Praxis had $926.1 million in cash and investments, with an additional $621 million from a January 2026 offering expected to fund operations into 2028, demonstrating financial stability.
See More
Baker Bros. Advisors Increases Stake in Praxis Precision Medicines
- Share Acquisition: Baker Bros. Advisors LP increased its stake in Praxis Precision Medicines by 437,000 shares in Q4 2025, with an estimated transaction value of $81.38 million, indicating strong confidence in the company's future prospects.
- Market Value Increase: Following the acquisition, Baker Bros. now holds 1,126,488 shares, with the quarter-end position value rising by $295.48 million, reflecting both stock price appreciation and active trading dynamics.
- Strong Financial Position: Praxis Precision Medicines ended 2025 with $926.1 million in cash and investments, and an additional $621 million from a January 2026 offering is expected to fund operations through 2028, showcasing a robust financial foundation.
- R&D Investment: The company reported $267.1 million in R&D expenses for 2025, with a full-year net loss of $303.3 million; however, its strategic focus on CNS therapeutics continues to attract investor interest due to significant revenue potential.
See More
Perceptive Advisors Increases Stake in Praxis Precision Medicines
- Stake Increase: Perceptive Advisors increased its stake in Praxis Precision Medicines by 431,432 shares during Q4 2025, with an estimated transaction value of $80.34 million, reflecting strong confidence in the company's future prospects.
- Market Value Growth: Following this purchase, Praxis's quarter-end market value increased by $505.38 million, indicating a dual impact from both the share purchase and subsequent stock price appreciation, showcasing market recognition of its clinical pipeline.
- Financial Position: As of February 17, 2026, Praxis shares were priced at $328.04, up 320% year-over-year, while the company reported $926 million in cash and investments, providing ample financial support for future commercialization efforts.
- R&D Investment: In 2025, Praxis's research and development spending reached $267 million, indicating a significant investment in multiple programs aimed at accelerating the development of its clinical-stage drug candidates.
See More
Perceptive Advisors Acquires 431,432 Shares of Praxis Precision Medicines
- Share Acquisition Details: Perceptive Advisors increased its stake in Praxis Precision Medicines by 431,432 shares during Q4 2025, with an estimated transaction value of $80.34 million, reflecting strong confidence in the company's future prospects.
- Position Value Growth: Following this acquisition, the value of Praxis's holdings reached $588.30 million, an increase of $505.38 million from the previous quarter-end, indicating significant stock price appreciation and positive investor sentiment.
- Financial Overview: As of February 17, 2026, Praxis shares were priced at $328.04, up 320% year-over-year, despite a net loss of $273.04 million in 2025, suggesting market optimism regarding its future product pipeline.
- R&D and Market Outlook: Praxis has submitted two NDAs to the FDA and is actively preparing for commercialization, with multiple clinical trial results expected in 2026, which could further enhance its market position in the central nervous system sector.
See More
Xenon Pharmaceuticals Reports Positive Phase 3 X-TOLE2 Study Results
- Positive Study Results: Xenon Pharmaceuticals announced positive topline results from the Phase 3 X-TOLE2 study of azetukalner in focal onset seizures, with a placebo-adjusted median percentage change of -42.7% in the 25 mg group, significantly outperforming the previous Phase 2b study results.
- Primary Endpoint Achieved: The study met its primary endpoint, with 54.8% of participants in the 25 mg group achieving at least a 50% reduction in monthly seizure frequency compared to 20.8% in the placebo group, demonstrating the efficacy of azetukalner.
- Future Application Plans: Xenon plans to submit a New Drug Application (NDA) to the FDA in Q3 2026, and if approved, azetukalner will be the only KV7 potassium channel opener available for epilepsy treatment, potentially transforming the treatment landscape for patients with uncontrolled seizures.
- Positive Market Reaction: Xenon shares rose 16.17% to $48.72 in premarket trading on Monday, reflecting strong investor response to the study results, while analysts maintain a Buy rating with an average price target of $56.78.
See More
Praxis Grants Restricted Stock Units to New Employees
- Employee Incentive Program: On March 2, 2026, Praxis Precision Medicines granted 2,931 restricted stock units to fourteen new non-executive employees, aimed at attracting top talent in compliance with Nasdaq Listing Rule 5635(c)(4).
- Stock Unit Vesting Schedule: The restricted stock units will vest in four equal annual installments, contingent upon the employees' continued employment, thereby aligning employee interests with the company's long-term goals and enhancing retention rates.
- Strategic Talent Acquisition: This grant is part of the 2024 Inducement Plan, specifically designed to attract individuals who were not previously employed by the company, highlighting Praxis's commitment to talent acquisition and its competitive edge in the biopharmaceutical industry.
- Company Overview: Praxis is a leading CNS precision neuroscience biopharmaceutical company focused on translating insights from genetic epilepsies into therapies for CNS disorders, boasting multiple late-stage product candidates that demonstrate strong R&D capabilities and market potential.
See More
Baker Bros. Increases Praxis Stake to 1.94% with $81.38M Purchase
- Stake Increase: Baker Bros. Advisors increased its stake in Praxis Precision Medicines by 437,000 shares during Q4 2025, valued at $81.38 million, indicating strong confidence in the company's future prospects.
- Market Valuation Growth: The post-trade valuation of Praxis increased by $295.48 million due to trading activity and price movements, reflecting positive market sentiment towards its clinical-stage therapies.
- R&D Investment: In 2025, Praxis reported R&D expenses of $267.1 million, with a net loss of $303.3 million, yet the company remains committed to advancing its treatments for central nervous system disorders.
- Cash Flow Position: As of the end of 2025, Praxis had $926.1 million in cash and investments, with an additional $621 million from a January 2026 offering expected to fund operations into 2028, demonstrating financial stability.
See More
Baker Bros. Advisors Increases Stake in Praxis Precision Medicines
- Share Acquisition: Baker Bros. Advisors LP increased its stake in Praxis Precision Medicines by 437,000 shares in Q4 2025, with an estimated transaction value of $81.38 million, indicating strong confidence in the company's future prospects.
- Market Value Increase: Following the acquisition, Baker Bros. now holds 1,126,488 shares, with the quarter-end position value rising by $295.48 million, reflecting both stock price appreciation and active trading dynamics.
- Strong Financial Position: Praxis Precision Medicines ended 2025 with $926.1 million in cash and investments, and an additional $621 million from a January 2026 offering is expected to fund operations through 2028, showcasing a robust financial foundation.
- R&D Investment: The company reported $267.1 million in R&D expenses for 2025, with a full-year net loss of $303.3 million; however, its strategic focus on CNS therapeutics continues to attract investor interest due to significant revenue potential.
See More
Perceptive Advisors Increases Stake in Praxis Precision Medicines
- Stake Increase: Perceptive Advisors increased its stake in Praxis Precision Medicines by 431,432 shares during Q4 2025, with an estimated transaction value of $80.34 million, reflecting strong confidence in the company's future prospects.
- Market Value Growth: Following this purchase, Praxis's quarter-end market value increased by $505.38 million, indicating a dual impact from both the share purchase and subsequent stock price appreciation, showcasing market recognition of its clinical pipeline.
- Financial Position: As of February 17, 2026, Praxis shares were priced at $328.04, up 320% year-over-year, while the company reported $926 million in cash and investments, providing ample financial support for future commercialization efforts.
- R&D Investment: In 2025, Praxis's research and development spending reached $267 million, indicating a significant investment in multiple programs aimed at accelerating the development of its clinical-stage drug candidates.
See More
Perceptive Advisors Acquires 431,432 Shares of Praxis Precision Medicines
- Share Acquisition Details: Perceptive Advisors increased its stake in Praxis Precision Medicines by 431,432 shares during Q4 2025, with an estimated transaction value of $80.34 million, reflecting strong confidence in the company's future prospects.
- Position Value Growth: Following this acquisition, the value of Praxis's holdings reached $588.30 million, an increase of $505.38 million from the previous quarter-end, indicating significant stock price appreciation and positive investor sentiment.
- Financial Overview: As of February 17, 2026, Praxis shares were priced at $328.04, up 320% year-over-year, despite a net loss of $273.04 million in 2025, suggesting market optimism regarding its future product pipeline.
- R&D and Market Outlook: Praxis has submitted two NDAs to the FDA and is actively preparing for commercialization, with multiple clinical trial results expected in 2026, which could further enhance its market position in the central nervous system sector.
See More
